Journal
KIDNEY INTERNATIONAL
Volume 89, Issue 3, Pages 524-526Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2015.12.038
Keywords
-
Categories
Funding
- Heart & Stroke/Richard Lewar Centre of Excellence Studentship
- Javenthey Soobiah Scholarship
- Queen Elizabeth II/Dr. Arnie Aberman Scholarship in Science and Technology
- University of Toronto Fellowship in the Department of Pharmacology and Toxicology
Ask authors/readers for more resources
Inhibition of sodium-glucose cotransporter 2 causes both glycosuria and natriuresis, leading to reductions in hyperglycemia, body weight, blood pressure, and proteinuria. The recently published EMPA-REG OUTCOME study demonstrated significant cardiovascular and mortality benefits of sodium-glucose cotransporter 2 inhibition with empagliflozin in patients with type 2 diabetes and established cardiovascular disease, and may suggest a broader role for sodium-glucose cotransporter 2 inhibition in patients with heart failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
